CTLA4 blockade broadens the peripheral T-cell receptor repertoire

Clinical Cancer Research

Volumn 20, Issue 9, 2014, Pages 2424-2432

  Robert, Lidia ^a   Tsoi, Jennifer ^b   Wang, Xiaoyan ^a   Emerson, Ryan ^c,d   Homet, Blanca ^a,e   Chodon, Thinle ^a   Mok, Stephen ^a,b   Huang, Rong Rong ^a   Cochran, Alistair J ^a   Comin Anduix, Begoña ^a,b   Koya, Richard C ^a,b   Graeber, Thomas G ^b   Robins, Harlan ^c,d   Ribas, Antoni ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d ADAPTIVE BIOTECHNOLOGIES   (United States)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; ANTINEOPLASTIC AGENT; COMPLEMENTARITY DETERMINING REGION; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BIOLOGY; CANCER STAGING; CLUSTER ANALYSIS; COMPLEMENTARITY DETERMINING REGION; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; DRUG EFFECTS; GENETIC VARIABILITY; GENETICS; LYMPHOCYTE COUNT; METABOLISM; METASTASIS; MIDDLE AGED; MONONUCLEAR CELL; MORTALITY; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLUSTER ANALYSIS; COMPLEMENTARITY DETERMINING REGIONS; COMPUTATIONAL BIOLOGY; CTLA-4 ANTIGEN; FEMALE; GENETIC VARIATION; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SEQUENCE ANALYSIS, DNA; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 84899750907     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2648     Document Type: Article

References (43)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
3. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009;27:1075-81.
4. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7.
5. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic Tlymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741-50.
6. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, MillhamR, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77.
7. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100: 4712-7.
8. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53.
9. Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 2004;27:478-9.
10. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005;28:593-8.
11. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter singlearm phase II study. Ann Oncol 2010;21:1712-7.
12. Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010; 16:1042-8.
13. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013;31:616-22.
14. Wilson KS, Kotb R. Is Tremelimumab Beneficial in Advanced Melanoma. J Clin Oncol 2013;31:2835-6.
15. Ribas A, Hauschild A, Kefford R. Reply to KS. Wilson et al. J Clin Oncol 2013;31:2836-7.
16. Wilgenhof S, Du Four S, Everaert H, Neyns B. Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports. Cancer Invest 2012;30:712-20.
17. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010;116:1767-75.
18. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009;15:6267-76.
19. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011;17:4101-9.
20. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 2009;4:e7887.
21. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, et al. Imaging of CTLA4 blockade-induced cell replication with (18)FFLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 2010;51:340-6.
22. Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M, et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 2009;15:2507-13.
23. Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, et al. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS ONE 2010;5:e12711.
24. Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, BernsteinSH, et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007;12:873-83.
25. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 2008;31: 294-309.
26. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res 2009;15:390-9.
27. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. Comprehensive assessment of T-cell receptor betachain diversity in alphabeta T cells. Blood 2009;114:4099-107.
28. Shannon CE. A mathematical theory of communication. Bell Syst Tech J 1948;27:379-423.
29. Pielou BC. Species-Diversity and Pattern-Diversity in the Study of ecological Succession. J Theor Biol 1966;10:370-83.
30. Fitzmaurice GM, Ravichandran C. A primer in longitudinal data analysis. Circulation 2008;118:2005-10.
31. Lehmann EL, D'Abrera HJM. Nonparametrics: statistical methods based on ranks. Englewood Cliffs, NJ: Prentice-Hall; 1998.
32. Team RC. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013. ISBN 3-900051-07-0, URL http://www.R-project.org.
33. Wilgenhof S, Du Four S, Vandenbroucke F, Everaert H, Salmon I, Lienard D, et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 2013;36:215-22.
34. Plaisier S, Taschereau R, Wong J, Graeber T. Rank-rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures. Nucleic Acids Res 2010;38:e169.
35. Neller MA, Burrows JM, Rist MJ, Miles JJ, Burrows SR. High frequency of herpesvirus-specific clonotypes in the human T cell repertoire can remain stable over decades with minimal turnover. J Virol 2013; 87:697-700.
36. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005;175:7746-54.
37. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 2004;27:354-67.
38. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008;105:20410-5.
39. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008;105:14987-92.
40. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 2008;6:22.
41. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, et al. CTLA4 blockade expands FoxP3 +regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008;112:1175-83.
42. Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Onc 2008;5:557-61.
43. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 2009;7:35.